New Clinical Advisory Board Members
-- Howard A. (Skip) Burris, III, M.D., is chief medical officer and
director of drug development at The Sarah Cannon Research Institute in
Nashville, where he is also an associate with Tennessee Oncology, PLLC.
Dr. Burris' research interests focus on developing investigational
agents and evaluating these compounds in Phase 1 and 2 clinical trials.
He has published papers on taxanes and topoisomerase I inhibitors. He
currently serves on the American Society of Clinical Oncology (ASCO)
Board of Directors and is a member of ASCO's Ethics Committee. He
received his medical degree from the University of South Alabama and
completed his residency and fellowship in hematology/oncology at Brooke
Army Medical Center in San Antonio. While there, he served as director
of clinical research at the Institute for Drug Development of The
Cancer Therapy and Research Center and was an associate professor at
The University of Texas Health Science Center.
-- E. David Crawford, M.D., is the E. David Crawford distinguished
professor of surgery, urology and radiation oncology, and head of the
Section of Urologic Oncology at the University of Colorado Health
Sciences Center in Denver. He also serves as the senior associate
director of the University of Colorado Comprehensive Cancer Center in
Denver. Dr. Crawford, the recipient of nearly 70 research grants, has
conducted research in the treatment of a
|SOURCE Poniard Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved